PURPOSE: Cisplatin resistance remains a barrier to organ-sparing and survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). Targeted therapies to overcome cisplatin-resistant HNSCC are being developed. METHODS AND MATERIALS: Cisplatin-sensitive parental HNSCC cell lines and cisplatin-resistant progeny were studied. Pretreatment HNSCC biopsies were used to construct tissue microarrays which were stained for p53 and Bcl-xL. RESULTS: HNSCC cell lines selected for cisplatin resistance had wild-type p53 and high levels of Bcl-xL. Expression of wild-type p53 in cell lines with low Bcl-xL enhanced cisplatin sensitivity. Expression of both Bcl-xL and wild-type p53 caused tumor cells to become cisplatin resistant. Patients whose tumors expressed low levels of p53 and Bcl-xL enjoyed the best organ preservation and disease-free survival whereas patients whose tumors expressed low levels of p53 and high levels of Bcl-xL had the worst outcome. Novel agents that inhibit Bcl-xL or activate p53 function may target cisplatin-resistant HNSCC. CONCLUSION: Cisplatin resistance in HNSCC is mediated, at least in part, by high Bcl-xL and functional p53.
PURPOSE:Cisplatin resistance remains a barrier to organ-sparing and survival of patients with advanced head and neck squamous cell carcinoma (HNSCC). Targeted therapies to overcome cisplatin-resistant HNSCC are being developed. METHODS AND MATERIALS: Cisplatin-sensitive parental HNSCC cell lines and cisplatin-resistant progeny were studied. Pretreatment HNSCC biopsies were used to construct tissue microarrays which were stained for p53 and Bcl-xL. RESULTS: HNSCC cell lines selected for cisplatin resistance had wild-type p53 and high levels of Bcl-xL. Expression of wild-type p53 in cell lines with low Bcl-xL enhanced cisplatin sensitivity. Expression of both Bcl-xL and wild-type p53 caused tumor cells to become cisplatin resistant. Patients whose tumors expressed low levels of p53 and Bcl-xL enjoyed the best organ preservation and disease-free survival whereas patients whose tumors expressed low levels of p53 and high levels of Bcl-xL had the worst outcome. Novel agents that inhibit Bcl-xL or activate p53 function may target cisplatin-resistant HNSCC. CONCLUSION:Cisplatin resistance in HNSCC is mediated, at least in part, by high Bcl-xL and functional p53.
Authors: Susan Urba; Gregory Wolf; Avraham Eisbruch; Francis Worden; Julia Lee; Carol Bradford; Theodoros Teknos; Douglas Chepeha; Mark Prince; Norman Hogikyan; Jeremy Taylor Journal: J Clin Oncol Date: 2005-12-27 Impact factor: 44.544
Authors: Joshua A Bauer; Douglas K Trask; Bhavna Kumar; Gerrit Los; Jason Castro; Julia Shin-Jung Lee; Jianyong Chen; Shaomeng Wang; Carol R Bradford; Thomas E Carey Journal: Mol Cancer Ther Date: 2005-07 Impact factor: 6.261
Authors: Keith G Wolter; Steven J Wang; Bradley S Henson; Shaomeng Wang; Kent A Griffith; Bhavna Kumar; Jianyong Chen; Thomas E Carey; Carol R Bradford; Nisha J D'Silva Journal: Neoplasia Date: 2006-03 Impact factor: 5.715
Authors: Christopher L Oliver; Joshua A Bauer; Keith G Wolter; Mathew L Ubell; Ajita Narayan; Kathleen M O'Connell; Susan G Fisher; Shaomeng Wang; Xihan Wu; Min Ji; Thomas E Carey; Carol R Bradford Journal: Clin Cancer Res Date: 2004-11-15 Impact factor: 12.531
Authors: Douglas K Trask; Gregory T Wolf; Carol R Bradford; Susan G Fisher; Kenneth Devaney; Mark Johnson; Timothy Singleton; Max Wicha Journal: Laryngoscope Date: 2002-04 Impact factor: 3.325
Authors: C R Bradford; S Zhu; G T Wolf; J Poore; S G Fisher; T Beals; K D McClatchey; T E Carey Journal: Otolaryngol Head Neck Surg Date: 1995-10 Impact factor: 3.497
Authors: Shadan Ali; Lalee Varghese; Lucio Pereira; Ozlem E Tulunay-Ugur; Omer Kucuk; Thomas E Carey; Gregory T Wolf; Fazlul H Sarkar Journal: Cancer Lett Date: 2009-02-23 Impact factor: 8.679
Authors: Naoki Ashimori; Benjamin D Zeitlin; Zhaocheng Zhang; Kristy Warner; Ilan M Turkienicz; Aaron C Spalding; Theodoros N Teknos; Shaomeng Wang; Jacques E Nör Journal: Mol Cancer Ther Date: 2009-04 Impact factor: 6.261
Authors: Matthew J Sikora; Joshua A Bauer; Monique Verhaegen; Thomas J Belbin; Michael B Prystowsky; Joseph C Taylor; J Chad Brenner; Shaomeng Wang; Maria S Soengas; Carol R Bradford; Thomas E Carey Journal: Cancer Biol Ther Date: 2008-05-20 Impact factor: 4.742
Authors: William A Michaud; Anthony C Nichols; Edmund A Mroz; William C Faquin; John R Clark; Shahnaz Begum; William H Westra; Hiroshi Wada; Paul M Busse; Leif W Ellisen; James W Rocco Journal: Clin Cancer Res Date: 2009-02-24 Impact factor: 12.531
Authors: Thomas J Ow; Carlos Thomas; Cory D Fulcher; Jianhong Chen; Andrea López; Denis E Reyna; Michael B Prystowsky; Richard V Smith; Bradley A Schiff; Gregory Rosenblatt; Thomas J Belbin; Thomas M Harris; Geoffrey C Childs; Nicole Kawachi; Nicolas F Schlecht; Evripidis Gavathiotis Journal: Laryngoscope Date: 2020-01-02 Impact factor: 3.325